2. Pearle M.S. Prevention of nephrolithiasis. Curr Opin Nephrol Hypertens 2001;10:203–209.

3. Pearle M.S., Calhoun E.A., Curhan G.C. Urologic Diseases of America Project. Urologic diseases in America project: urolithiasis. J Urol. 2005;173:848–857.

4. Sorokin I., Mamoulakis C., Miyazawa K., Rodgers A., Talati J., Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301–1320.

5. Aleksandrov V.P., Tiktinskii O.L. et al. Features of stone formation in the kidneys in patients in families burdened with urolithiasis. Urologiya i nefrologiya. 1993;3:16–19. Russian (Александров В.П., Тиктинский О.Л. и соавт. Особенности камнеобразования в почках у больных в семьях, отягощенных уролитиазом. Урология и нефрология. 1993;3:16–19).

6. Tiktinskii O.L., Aleksandrov V.P. Urolithiasis. SPb. «Piter», 2000. s. 384. Russian (Тиктинский О.Л., Александров В.П. Мочекаменная болезнь. СПб. «Питер», 2000. С. 384).

7. Voshchula I.V. Urolithiasis. Etiotropic and pathogenetic treatment, prevention. Minsk. 2006. Russian (Вощула И.В. Мочекаменная болезнь. Этиотропное и патогенетическое лечение, профилактика. Минск. 2006).

8. Dzhavad-zade S.M. Urolithiasis in the endemic region: etiopathogenesis, clinic, treatment. Dr.Med.Sci. Thesis. M., 1997. Russian (Джавад-заде С.М. мочекаменная болезнь в эндемическом регионе: этиопатогенез, клиника, лечение. Дисс. докт. мед наук. М., 1997).

9. Dzhavad-zade S.M. Modern view on the pathogenesis, course and treatment of urolithiasis. Urologiia. 1999;5:10–12. Russian (Джавад-заде С.М. Современный взгляд на патогенез, течение и лечение мочекаменной болезни. Урология. 1999;5:10–12).

10. Voshchula V.I., Nitkin D.M. Metabolic disorders in urolithiasis. Uchebno-metodicheskoe posobie. Minsk. BelMAPO, 2004. S. 28. Russian (Вощула В.И., Ниткин Д.М. Метаболические нарушения при мочекаменной болезни. Учебно-методическое пособие. Минск. БелМАПО, 2004. С. 28).

11. Gres’ A.A., Voshchula V.I., Nitkin D.M., rybina I.L. Study of biochemical indicators of urine in healthy individuals. Aktual’nye voprosy urologii: tezisy dokl. 6-go belor-pol’skogo simp. Minsk, 2003. S. 19–21. Russian (Гресь А.А., Вощула В.И., Ниткин Д.М., Рыбина И.Л. изучение биохимических показателей мочи у здоровых лиц. Актуальные вопросы урологии: тезисы докл. 6-го белор-польского симп. Минск, 2003. С. 19–21).

12. Daudon M., Doré J.-C., Jungers P., Lacour B. Changes in stone composition according to age and gender of patients: a multivariate epidemiological approach. Urol. Res. 2004;32:241–247.

13. Pearle M.S., Calhoun E.A., Curhan G.C. Urologic Diseases of America Project. Urologic diseases in America project: urolithiasis. J Urol. 2005;173:848–57.

14. Daudon M., Doré J.-C., Jungers P., Lacour B. Changes in stone composition according to age and gender of patients: a multivariate epidemiological approach. Urol. Res. 2004;32:241–247.

15. Adair L.S., Popkin B.M. Are child eating patterns being transformed globally? Obes Res. 2005;13:1281–1299.

16. DeMaria E.J. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176–2183.

17. Konstantinova O.V. Prediction and principles of prevention of urolithiasis. Dr.Med.Sci. Thesis. M., 1999. Russian (Константинова О.В. Прогнозирование и принципы профилактики мочекаменной болезни. Дисс. докт. мед. наук. М., 1999).

18. Dzeranov N.K. Treatment of urolithiasis – a comprehensive medical problem. Quality of life. Meditsina. 2005;2(9):3–8. Russian (Дзеранов Н.К. Лечение мочекаменной болезни – комплексная медицинская проблема. Качество жизни. Медицина. 2005;2(9):3–8).

19. Katkova V.N. Urinary stones: mineralogy and genesis. Syktyvkar: Komi nauchnyi tsentr UrO RAN. 1996. Russian (Каткова В.Н. Мочевые камни: минералогия и генезис. Сыктывкар: Коми научный центр УрО РАН. 1996).

20. Kok D.J. Clinical implications of physicochemistry of stone formation. Endocr Metab Clin N Am. 2002;31:855–867.

21. Hess B., Kok D.J. Nucleation, growth and aggregation of stone forming crystals. In: Coe FL, Favus M, Pak CYC, Parks J, Preminger G, editors. Chapter 1: kidney stones: medical and surgical management. Raven Press. 1995:3–32.

22. Pak C.Y.C. Calcium Urolithiasis: Pathogenesis, Diagnosis, and Management. New York and London. Plenum Medical Book Company. 1978. Р. 162.

23. Abraham P.A., Smith Ch.L. Medical Evaluation and Management of Calcium Nephrolithiasis. Med. Clin. North. Am. 1984;68(2):281–299.

24. Buck A.C. Risk factors in idiopatic stone disease. Scientific Foundation of Urology: 3 ed. Eds. L.D. Chisholm, W.R. Fair. Oxford, Chicago, 1990. P. 176–192.

25. Andriani R.T., Carson C.C. Urolithiasis. Clin. Symposia.1986;38(3):5–25. Someren A. Urologic Pathology with Clinical and Cardiologic Corrections. New York, Toronto, London, 1989.

26. Jones W.F., Waterhouse R.L., Resnick M.I. The evaluation of urinary protein pattern in a stone – forming animal model using two dimensional polyacrylamide gel electrophoresis. J Urol. 1991;145(4):868–874.

27. Hess B. Neue pathophysiologische Aspecte der Nephrolithiasis. Schwez. Med. Wsch. 1989;119(26):929–934.

28. Nancollas G.H., Smesko S.A., Campbello A.A., Richardson C.F., Johansson M., Iadiccico P.A., Binetto J.P., Binetto M. Physical chemical studies of calcium oxalate crystallization. Am. J. Kidney Dis. 1991;17(4):392–395.

29. Litvitskii P.F. Pathophysiology: Textbook: in 2 volumes. M.:GEOTAR-MED, 2002. 365 p. Russian (Литвицкий П.Ф. Патофизиология: Учебник: в 2 томах. М.:ГЭОТАР-МЕД, 2002. 365 с.).

30. Rendall A. The origin and growth of renal calculi. Ann Surg. 1937;105:1009–1027.

31. Randall A. Papillary pathology as a precursor of primary renal calculus. J Urol. 1940;44:580.

32. Randall A. The etiology of primary renal calculus. International Abstract of Surgery. 1940;71:209.

33. Evan A.P., Lingerman J.E., Coe F.L. et al. Renall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. 2003;111:607–616.

34. Evan A., Lingeman J., Coe F.L., Worcester E. Randall’s plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int. 2006;69:1313–1318.

35. Kim S.C., Coe F.L., Tinmouth W.W. et al. Stone formation is proportional to papillary surface coverage be rendall’s plaque. J Urol. 2005;173:117–119.

36. Matlaga Br, Williams Jr Jc, Kim S.C. et al. Еndoscopic evidence of cflculi attachment to Rendall’s plaque L. Urol 2006;175:1720–1774.

37. Williams Jr Jc, Matlaga Br, Kim SC et al. Calcium oxalate calculi found attached to the renal papilla: preliminary for early mechanisms in stone formation. J Endourol. 2006;20:885–890.

38. Evan A.P., Lingerman J.E., Coe F.L., Worcester E.M. Role of interstitial apapite plaque in the pathogenesis of the common calcium oxalate stone. Semin Nephrol. 2008;28:111–119.

39. Evan A.P., Worcester E.M., Coe F.L., Williams J.Jr., Lingeman J.E. Mechanisms of human kidney stone formation. Urolithiasis. 2015,43(suppl.1):19–32.

40. Evan A.P., Coe F.L., Lingeman, J.E., Shao Y., Sommer A.J., Bledsoe S.B., Anderson J.C., Worcester E.M. Mechanism of formation of human calcium oxalate renal stones on Randall’s plaque. Anat. Rec. 2007;290:1315–1323.

41. Kidney stones Nature Reviews Disease Primers 2, Article number: 16008 (2016) Doi:10.1038/nrdp.2016.8.

42. Finlayson B., Reid F. The expectation of free and fixed particles in urinary stone disease. Invest. Urol. 1978;15:442–448.

43. Kok D.J., Khan S.R. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int. 1994;46:847–854.

44. Khan S.R. Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones. Scanning Microsc. 1995;9:89–100.

45. Khan S.R., Canales B.K. Unified theory on the pathogenesis of Randall’s plaques and plugs. Urolithiasis. 2015;43(Suppl. 1):109–123.

46. Khan S.R., Canales B.K. Unified theory on the pathogenesis of Randall’s plaques and plugs. Urolithiasis. 2015;43(Suppl. 1):109–123.

47. Khan S.R., Rodriguez D.E., Gower L.B., Monga M. Association of Randall plaque with collagen fibers and membrane vesicles. J. Urol. 2012;187:1094–1100.

48. Bird V.Y., Khan S.R. How do stones form? Is unification of theories on stone formation possible? Arch Esp Urol. 2017;70(1):12–27.

49. Kaufman D.W., Kelly J.P., Curhan G.C. et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol. 2008;19(6):1197–1203.

50. Tsuji H., Wang W., Sunil J. et al. Involvement of renin–angiotensin–aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury. World J Urol. 2016;34(1):89–95.

51. Khand F.D., Gordge M.P., Robertson W.G., Noronha-Dutra A.A., Hothersall J.S. Mitochondrial superoxide production during oxalate-mediated oxidative stress in renal epithelial cells. Free Radical Biology & Medicine. 2002;32(12):1339–1350.

52. Umekawa T., Tsuji H., Uemura H., Khan S.R. Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU International. 2009;104(1):115–120.

53. Khan S.R., Khan A., Byer K.J. Temporal changes in the expression of mRNA of NADPH oxidase subunits in renal epithelial cells exposed to oxalate or calcium oxalate crystals, Nephrology Dialysis Transplantation. 2001;26(6):1778–1785.

54. Joshi S., Peck A.B., Khan S.R. NADPH oxidase as a therapeutic target for oxalate induced injury in kidneys. Oxidative Medicine and Cellular Longevity. 2013;2013:18.

55. Cao L.-C., Honeyman T.W., Cooney R., Kennington L., Scheid C.R., Jonassen J.A. Mitochondrial dysfunction is a primary event in renal cell oxalate toxicity. Kidney International. 2004;66(5):1890–1900.

56. Khan S.R. Crystal/cell interaction and nephrolithiasis. Arch. Ital. Urol. Androl. 2011;83:1–5.

57. Khan S.R. Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol. 2013;189(3):803–811.

58. Golovanov S.A., Yanenko E.K., Dzeranov N.K., Drozhzheva V.V., Beshliev D.A., Kon’kova T.A. Lipid peroxidation and antioxidant system in patients with urolithiasis after remote lithotripsy. Urologiya i nefrologiya. 1998;2:14–16. Russian (Голованов С.А., Яненко Э.К., Дзеранов Н.К., Дрожжева В.В., Бешлиев Д.А., Конькова Т.А. Липидная пероксидация и антиоксидантная система у больных мочекаменной болезнью после дистанционной литотрипсии. Урология и нефрология. 1998;2:14–16).

59. Liang Q., Li X., Zhou W., Su Y., He S., Cheng S., Lu J., Yan Y., Pei X., Qi J. et al. An Explanation of the Underlying Mechanisms for the In Vitro and In Vivo Antiurolithic Activity of Glechoma longituba. Oxid. Med. Cell. Longev. 2016, 3134919.

60. Fasano J.M., Khan S.R. Intratubular crystallization of calcium oxalate in the presence of membrane vesicles: An in vitro study. Kidney Int. 2001;59:169–178.

61. Stoller V.L., Meng M.V., Abrahams H.M., Kane J.P. The primary stone event; a new hypothesis involving a vascular etiology. J Urol. 2004;171:1920–1924.

62. Stoller M.L., Low R.K., Shami G.S. et al. High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall’s plaque formation. J Urol. 1996;156:1263.

63. Sampaio F.J., Aragao A.H. Anatomical relationship between the intrarenal arteries and the kidney collecting system. J Urol. 1990;143:679–81.

64. Bushinsky D.A., Monk R.D. Electolyte quintet: calcium. Lancet. 1998;352:306–11.

65. Carr R.J. A new theory of the formation of renal calculi. Brit J Urol 26:p.105, 1954; Randall A. The origin and growth of renal calculi. Ann Surg. 1937;105:1009.

66. Robertson W.G., Peacock M., Nordin B.E. Calcium oxalate crystalluria and urine saturation in recurrent renal stone-formers. Clin. Sci. 1971;40:365–374.

67. Khan S.R., Hackett R.L. Retention of calcium oxalate crystals in renal tubules. Scanning Microsc. 1991;5:707–711.

68. Khan S.R., Finlayson B., Hackett R.L. Experimental calcium oxalate nephrolithiasis in the rat. Role of the renal papilla. Am. J. Pathol. 1982;107:59–69.

69. Grases F., Söhnel O. Can Randall’s plug composed of calcium oxalate from via the free particle mechanism? BMC Urology. 2017;17:80.

70. Finlayson B., Reid F. The expectation of free and fixed particles in urinary stone disease. Investig Urol. 1978;15:442–448.

71. Kramer G., Klingler H.C., Steiner G.E. Role of bacteria in the development of kidney stones. Curr. Opin. Urol. 2000;10(1):35–38.

72. Barannik S.V. The history of the discovery of nanobacteria. Nauki o cheloveke – Sbornik statei po materialam tret’ego kongressa molodykh uchenykh i spetsialistov. Tomsk, SGMU. 2002. Russian (Баранник С.В. История открытия нанобактерии. Науки о человеке – Сборник статей по материалам третьего конгресса молодых учёных и специалистов. Томск, СГМУ. 2002).

73. Folk R.L. SEM imaging of bacteria and nanobacteria in carbonate sediments and rocks. J Sediment Petrol. 1993:63:990.

74. Leiske J.C., Toback F.G. Renal cell-urinary crystal interaction. Curr Opin Nephrol Hypertens. 2000;9:349.

75. Martel J., Wu C.Y., Young J.D. Translocation of mineralo-organic nanoparticles from blood to urine: a new mechanism for the formation of kidney stones? Nanomedicine (Lond). 2016.

76. Evan A.P. et al. Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones. Anat. Rec. (Hoboken). 2008;291:325–334.

77. Khan S.R., Gambaro G. Role of osteogenesis in the formation of Randall’s plaques. Anat. Rec. (Hoboken). 2015;299:5–7.

78. Mezzabotta F. et al. Spontaneous calcification process in primary renal cells from a medullary sponge kidney patient harbouring a GDNF mutation. J. Cell. Mol. Med. 2015;19:889–902.

79. Meyer J.L., Bergert J.H., Smith L.H. Epitaxial relationships in urolithiasis: the calcium oxalate monohydrate–hydroxyapatite system. Clin. Sci. Mol. Med. 1975;49:369–374.

80. Højgaard I., Fornander A.M., Nilsson M.A., Tiselius H.G. The effect of pH changes on the crystallization of calcium salts in solutions with an ion composition corresponding to that in the distal tubule. Urol. Res.1999;27:409–416.

81. Tiselius H.-G. A hypothesis of calcium stone formation: an interpretation of stone research during the past decades. Urol. Res. 2011;39:231–243.

82. Sethman I., Grohe B., Kleebe H.-J. Replacement of hydroxyapatite by whewellite: implications for kidney stone formation. Miner. Mag. 2014;78:91–100.

83. Baumann J.M., Affolter B. From crystalluria to kidney stones, some physicochemical aspects of calcium nephrolithiasis. World J Nephrol. 2014;3(4):256–267.

84. Saw N.K., Rao P.N., Kavanagh J.P. A nidus, crystalluria and aggregation: key ingredients for stone enlargement. Urol Res. 2008;36(1):11–15.

85. Haggitt R.C., Pitcock J.A. Renal medullary calcifications: a light and electron microscopic study. J. Urol. 1971;106:342–347.